NCT04008524Available不适用
A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Available
- 试验地点
- 1
研究概览
简要总结
This project is intended to provide CAR-T cell therapy products for patients with severely life-threatening relapsed and refractory hematological malignancies. These patients have been previously treated sufficiently, currently have no other treatment methods available, and do not meet the inclusion criteria of other clinical trial projects in the process of subject recruitment or meet their exclusion criteria. This project is designed to meet the urgent clinical needs of individual patients.
研究设计
- 研究类型
- Expanded Access
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients suffering from a hematological malignancy that is severely life-threatening or seriously affects the patient's quality of life and has no effective treatment available, who not meet the inclusion/exclusion criteria for other clinical trials in the process of subject recruitment, or who are unable to obtain other study drugs or participate in clinical studies/trials for some reason (regional or time restriction, etc., or the recruitment of subjects for clinical studies/trials has ended but the drug has not yet been approved for marketing in China);
- •Patients who are definitely diagnosed with the corresponding target-positive relapsed and refractory hematological malignancies, including but not limited to the following circumstances:
- •Patients who do not meet the inclusion/exclusion criteria for existing clinical trials, such as age <18 years, ECOG >1, extramedullary recurrence, persistent or repeatedly positive for minimal residual disease;
- •Patients who have relapsed after remission following CAR-T cell therapy, and are expected as judged by the investigator to benefit more from re-use of the same cell or sequential use of other CAR-T cells compared with the risk;
- •The quantity of CAR-T cells produced does not meet the release criteria of production quality inspection, but is >0.1× 106/kg CAR positive T cells, and the investigator judges that the expected benefit of cell infusion is greater than the risk;
- •The disease progresses rapidly after cell collection and before infusion, and the investigator judges that the expected benefit of cell infusion is greater than the risk;
- •Patients who have relapsed after autologous/heterogeneous hematopoietic stem cell transplantation (including those positive for minimal residual disease);
- •Other circumstances where the investigator judges that the expected benefit of cell infusion is greater than the risk.
- •Patients with appropriate bone marrow reserve: such as lymphocyte count >0.3×109/L;
- •Patients with proper heart, lung, liver, kidney and coagulation functions;
- •The selected patients or their legal representatives voluntarily sign the informed consent form.
排除标准
- •Patients who are positive for any of HIV antibody, TP antibody, HBsAg and HCV antibody.
- •Patients with a history of epilepsy or other central nervous system diseases.
- •Patients with evidence of currently uncontrollable serious active infections (e.g., sepsis, bacteremia, fungemia, viremia, etc.).
- •Patients with other conditions making the patients unsuitable for receiving cell therapy as judged by the investigator.
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Tissue Study in Patients Undergoing CAR-T Cell Therapy (CAR_21_01)CAR-T Therapy ComplicationsNCT04892433IRCCS Azienda Ospedaliero-Universitaria di Bologna150
Unknown
早期 1 期
CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple MyelomaRelapsed or Refractory Multiple MyelomaNCT04626752Hebei Senlang Biotechnology Inc., Ltd.50
尚未招募
1 期
A Study of CAR-T Cells in Subjects with Autoimmune DiseasesAutoimmune DiseasesNCT06762119Zhejiang University6
尚未招募
早期 1 期
First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive LymphomaRefractory Non-Hodgkin LymphomaRelapsed Non-Hodgkin LymphomaNCT06097455Fundacion Clinic per a la Recerca Biomédica40
尚未招募
1 期
Multi-CAR T Cell Therapy Targeting CD7-positive MalignanciesAcute Myeloid LeukemiaT-cell Acute Lymphoblastic LeukemiaT-cell Acute Lymphoblastic LymphomaNK Cell LymphomaNCT04033302Shenzhen Geno-Immune Medical Institute30